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ABSTRACT
The general consensus among sport and exercise
genetics researchers is that genetic tests have no role to
play in talent identification or the individualised
prescription of training to maximise performance.
Despite the lack of evidence, recent years have
witnessed the rise of an emerging market of direct-to-
consumer marketing (DTC) tests that claim to be able to
identify children’s athletic talents. Targeted consumers
include mainly coaches and parents. There is concern
among the scientific community that the current level of
knowledge is being misrepresented for commercial
purposes. There remains a lack of universally accepted
guidelines and legislation for DTC testing in relation to
all forms of genetic testing and not just for talent
identification. There is concern over the lack of clarity of
information over which specific genes or variants are
being tested and the almost universal lack of appropriate
genetic counselling for the interpretation of the genetic
data to consumers. Furthermore independent studies
have identified issues relating to quality control by DTC
laboratories with different results being reported from
samples from the same individual. Consequently, in the
current state of knowledge, no child or young athlete
should be exposed to DTC genetic testing to define or
alter training or for talent identification aimed at
selecting gifted children or adolescents. Large scale
collaborative projects, may help to develop a stronger
scientific foundation on these issues in the future.
INTRODUCTION—DIRECT-TO-CONSUMER
MARKETING
The general consensus among sport and exercise
genetics researchers is that genetic tests, based on
current knowledge, have no role to play in talent
identification or the individualised prescription of
training to maximise performance. Despite the lack
of evidence, recent years have witnessed the rise of
an emerging market of direct-to-consumer market-
ing (DTC) tests that claim to be able to identify
children’s athletic talents. Targeted consumers
include mainly coaches and parents. Early talent
identification is seen as a starting point to success
and on the basis of the results of the genetic tests
parents and coaches are led to believe that they can
acquire knowledge to plan and invest in a child’s
future. It is vitally important that sport and exercise
medicine practitioners are fully aware of the state
of the evidence in relation to genetic testing and
the limitations of current knowledge. This article
reviews the issues around the currently available
evidence behind the genetic testing, comments on
the ethical considerations and makes recommenda-
tions about such tests.
STATEMENT ON BACKGROUND TO THE
CONSENSUS PROCESS
A group of world experts in the field of genomics,
exercise, sport performance, disease, injury and
antidoping gathered with the International
Federation of Sports Medicine (FIMS) Scientific
Commission for a symposium to discuss the current
state of knowledge and to share ideas. One key
concern was the misuse of research evidence and
the misinformation about genetic testing, particu-
larly when marketed directly to the public, coaches
or parents. This is known as DTC testing for the
purpose of talent identification and to assess poten-
tial for future sports performance. There have been
a variety of documents that have addressed issues
for DTC Genetic Testing in relation to screening
for disease, or to identifying genetic carriers,
including those from the European Workshop on
Genetic Testing Offer in Europe, the Human
Genetics Commission (UK), American College of
Medicine Genetics among others.1–3 However,
these documents relate mainly to testing for disease
states or heritability of conditions and no organisa-
tion has specifically addressed the issue in regard to
the world of sport for talent identification.
The sports medicine community has a duty of
care to protect the health and well-being of athletes
based on the current scientific knowledge.
The consensus statement was developed across
four areas:
1. Genetics—expert opinion of the scientific evi-
dence in the field of genomics, exercise, sport per-
formance from the participants of the Genomics,
Genetics and Exercise Biology Symposium.
2. Sports medicine—consideration of the impact
of DTC testing for young athletes and the need
for education for sport and exercise medicine
practitioners by the FIMS Scientific
Commission.
3. Ethical and Legal—independent international
expert review of this document.
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4. An internet review of DTC tests commercially available—In
June 2015, internet searches were conducted from within
the UK to identify commercially-available sport and
exercise-related genetic tests for humans, a follow-up to a
similar analysis conducted in June 2013.4 As in previous
reports, four English language internet search terms
GENETIC, TEST, EXERCISE and SPORT were used in a
simple search in two popular internet search engines
(Google and Bing), as a potential consumer might do. In
addition, other commercially available sport and
exercise-related genetic tests, of which the authors were
already aware, were included in the results. The websites of
the commercial operations identified were explored manu-
ally and, if available, details about the numbers and identities
of genetic variants being tested were identified. The
recorded number of variants tested, and the names of the
genes corresponding to the variants tested, required some
subjective interpretation for their relevance to sport and
exercise where this was not clear on the websites. For
example, genetic tests marketed in relation to body compos-
ition phenotypes, but not clearly marketed as having a direct
interaction with exercise, were not included. In addition, in
some instances gene names but not specific variant details
were identified, so some assumptions have been made
regarding the precise variants being tested in those cases.
This statement does not relate to genetic testing for disease or
specifically for cardiovascular conditions predisposing to sudden
death related to exercise or sports performance.
SANTORINI 2015 CONSENSUS QUESTIONS
What are the issues around DTC genetic testing?
The science of genomics has advanced over the past decade at a
rate unimagined by the medical scientific community. Not only
is genetic testing becoming more commonplace in the clinical
setting, but it has also reached the general public. Testing has
also become much cheaper. From the $2.7billion it cost to
sequence the first whole human genome, it now costs less than
$1000 and continues to fall.5 For analysis of specific variants
this is even less, which is why companies can offer genetic
testing to the public on a commercial basis. However, while the
price of sequencing or genotyping has dramatically dropped,
the interpretation of what the results mean is still at an early
stage.6–10 Any genetic test should be evaluated against four
main criteria: analytic validity, clinical validity, clinical utility
and the associated ethical, legal and social implications.11
The pace of advance in sequencing and genotyping technol-
ogy has far exceeded the pace of change in related regulation.
Testing is poorly regulated with no worldwide agreement as illu-
strated by the following examples. Legislation currently varies
from country to country in Europe. While France, Germany,
Portugal and Switzerland have specific legislation that defines
that genetic tests can only be carried out by a medical doctor,
there is currently no regulation in the UK.12 A new draft
European Union law is still under negotiation between member
states. It would require companies to provide scientific evidence
for claims, and restrict or ban sales of genetic tests directly to
consumers.1 The In Vitro Diagnostics (IVD) Regulation passed
first reading in the European Parliament in 2014 and is cur-
rently under negotiation at the Council, representing member
states.13 This new law would require companies to provide evi-
dence of the clinical validity of their genetic tests and would
require medical supervision of testing. Australia has recently
amended the Therapeutic Goods Act ( July 2014) to regulate
the supply and advertising of DTC genetic testing. This testing
is prohibited in Australia, except where specifically approved by
the Therapeutic Goods Administration (TGA), which includes
proof that it is being performed in an accredited laboratory with
sufficient clinical validity and utility. Companies can take tests to
market without any independent analysis to verify their claims.
In the USA, The Food and Drug Administration (FDA) has the
authority to regulate genetic tests, but has only regulated the
relatively small number of genetic tests sold to laboratories as
kits. Although the FDA plans to expand its regulation to all
genetic tests, this has not yet occurred.14 A report by USA
Government Accountability Office (GAO) to the US Senate
highlights the problem:15 “A genetic test is considered by the
FDA to be a medical device only if it is manufactured as a free-
standing ‘kit’ and sold to a laboratory. Presently, though, most
genetic tests are not sold as kits but are manufactured in-house
by clinical laboratories. In these cases, the laboratory itself
decides whether a test has sufficient ‘clinical validity’ (ie, is suffi-
ciently effective at measuring what it purports to measure).
Although all clinical laboratories must be approved under the
Clinical Laboratory Improvement Amendments of 1988 (CLIA)
and meet general standards applicable to all laboratories, there
is no genetic testing specialty under CLIA.” The absence of
monitored quality control at the laboratory is also an issue. In
the GAO report, samples of DNA from the same people were
sent under different names and to different laboratories yet dif-
ferent genetic variants were reported for the same individual.15
Of concern also to exercise and sport geneticists is that there
are DTC health-related tests aimed at giving nutritional and life-
style information based on a limited genetic analysis, sometimes
called ‘nutrigenetic’ tests. In this case, the individual is often
encouraged to purchase multivitamin and mineral products. The
GAO report concluded that the “results encourage the purchase
of supplements that are overpriced, make unproven medical
claims, and may even be harmful”.15
What DTC tests are currently available?
Thirty-nine companies were identified as providing DTC genetic
tests that were marketed in relation to sport or exercise per-
formance or injury. For 21 of the 39 companies (54%), it was
not possible to identify the specific DNA sequence variants
tested. For the 18 companies that did present information about
their genetic tests on their websites, the most commonly-tested
variant was the ACTN3 R577X polymorphism that was tested
by 16 of those 18 companies (89%). The second most
commonly-tested variant was the ACE I/D polymorphism that
was tested by 11 of those 18 companies (61%). The median
number of variants tested by the 18 companies was 6, ranging
from 1 to 27.
Who are they aimed at, who can request them and what do
they claim to show?
DTC tests are aimed at individuals, coaches, parents, athletes and
sports teams but indeed anyone who is prepared to pay for the
test, and willing to send a saliva sample or buccal smear, can
request a test. Since the sample collection process is simple it can
be completed at home by any individual and mailed to a labora-
tory anywhere in the world. The claims of DTC websites in rela-
tion to sport performance and talent identification are numerous
and concerning as they are largely without scientific foundation.
Samples of these claims are shown in the box 1 below.
Since the last comparable survey of DTC4 the number of
companies providing DTC genetic tests appears to have almost
doubled from 22 identified in 2013 to 39 identified in 2015.
Only 14 of the original 22 companies identified appear to still
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operate commercially, meaning that eight have apparently
ceased to operate while 25 new companies have emerged during
the past 2 years. It was observed that some of the companies
listed in box 1 appear to either be linked to each other in some
way (perhaps rebranded for different markets or countries/cul-
tures), or linked to local ‘clinics’ (not included in box 1) via
which the genetic tests are marketed. Several of the companies
use their clients’ genetic test results as opportunities to offer
other aspects of their commercial activities for which additional
fees are charged, such as training advice and especially nutri-
tional supplements. However, the evidence to support linking
specific training advice and nutritional supplements based on
genetic data is extremely weak. Of the companies we identified,
54% of the companies offering DTC genetic tests related to
exercise and sport do not publicly state which genetic variants
they rely on. While commercial pressures undoubtedly exist, it
is impossible for anyone—consumer, academic scholar or others
—to scrutinise the service provided by the companies if the
detail is not presented to the public. Quite literally millions of
genetic tests could theoretically be conducted, so the choice of
which variants are tested—and how the results are interpreted—
is absolutely fundamental to the usefulness of the test. The
reasons for such apparent secrecy are presumably commercial
sensitivity in part, although it is tempting to conclude that
failing to publicise the tests conducted is a tacit admission that
the scientific evidence supporting the genetic variants chosen is
weak.16 17
The UK Human Genetics Commission, which was disbanded
in 2012, developed guidelines in relation to marketing of DTC
genetic tests. These suggest that the test provider should comply
with any legislation or voluntary codes for advertising of
medical tests and that they should also comply with more
general guidance (including legal guidance) covering consumer
advertising.2 At a minimum, advertising should:
▸ Accurately describe both the characteristics and the limita-
tions of the tests offered;
▸ Not overstate the utility of a genetic test;
▸ Make sure that any claim made about the clinical validity of
a test is supported by relevant evidence published in peer
reviewed scientific literature;
▸ Recognise that the test provider should be aware of the risk
of bias when quoting evidence and ensure that evidence is
presented.
Furthermore they suggest that the evidence of the association
between a genetic marker and a trait should be validated at
genome-wide significance level (p<5×10−8) in more than one
large case–control study and in a cohort of the ethnic/geo-
graphic background relevant to the client. This is particularly
relevant to talent identification or performance testing where
the studies to date are limited in ethnicity and geographic back-
ground. In 2008, the Federal Trade Commission (FTC) in the
USA issued warnings to consumers that “no standards govern
the reliability or quality of at-home genetic tests. The FDA and
Centers for Disease Control and Prevention recommend that
genetic tests be done in a specialised laboratory and that a
doctor or counsellor with specialised training interpret the
results.” Perhaps it is unsurprising then that the GAO report in
2010 to the US Senate is titled: ‘Direct-To-Consumer Genetic
Tests—Misleading Test Results Are Further Complicated by
Deceptive Marketing and Other Questionable Practices’.15
What are the ethical and legal issues around consent and
data protection for companies providing this testing?
There is a consensus in the medical scientific community that
genetic tests should be carried out only after the person con-
cerned has given free and informed consent. This can only be
provided when a consumer/patient has received sufficient rele-
vant information about the genetic test in such a manner that
they are able to understand the risks, benefits, limitations and
implications of the genetic test, whose consequences may be
indirect and long term. Thus, for example, test data may also
have implications in the future for purchase or provision of
health or life insurance.
In the UK, the Human Genetics Commission produced guide-
lines around DTC Genetic Testing services but these had no
statutory authority.2 It includes clear guidance on consent and
includes the following: “Separate, specific, informed consent
should be requested by the test provider if the test provider
wishes to perform further tests that are not covered by the ori-
ginal consent or if biological samples are to be stored by the test
provider after the consumer has been provided with the genetic
test results. Likewise, separate informed consent should be
requested by the test provider before biological samples are used
for any secondary purposes, for example, research, or before
any third party is permitted access to biological samples.”
In relation to children it offers the following guidance
“Genetic tests in respect of children when, according to applic-
able law, that child does not have capacity to consent should
normally be deferred until the attainment of such capacity,
unless other factors indicate that testing during childhood is
clinically indicated. If postponement would be detrimental to
the child’s health, or the management of the child’s health may
be altered significantly depending on the test result, then testing
Box 1 Examples of claims from direct-to-consumer
marketing websites
▸ Discover how your genes contribute to your athletic traits;
▸ Personalise your training based on your sports genetics
results;
▸ Take advantage of your inherent strengths and overcome
your limitations;
▸ Gives parents and coaches early information on their child’s
genetic predisposition for success in team or individual
speed/power or endurance sports;
▸ Genetic predisposition determination can be valuable in
outlining training and conditioning programmes necessary
for athletic and sport development;
▸ Test results may be used later in development with other
athletic performance;
▸ We use your DNA results to help you lose fat, get lean, build
muscle, get fitter;
▸ Genetic test of athletic abilities describes:
– better or equal disposition to engage in either endurance
sports or power sports;
– the score of genetic predisposition to engage in either
endurance or power sports on 8-point scale;
– the regulation of blood supply, work capacity and
metabolic processes in your muscles;
– the type of muscle fibres—fast-twitch or slow-twitch;
– the availability of energy in cells;
– the availability of constant energy supply in your muscles
during exercise;
– the presence and extent of protection of your skeletal
muscles against fatigue.
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should be organised by a health professional who has responsi-
bility for ensuring that any medical intervention or screening
indicated will be arranged and proper arrangements made for
any subsequent care.” These principles of the Human Genetics
Commission are applicable to ‘lifestyle/behavioural’ traits such
as performance capacities if they are deemed by to be ‘high
impact’, which is open to debate. For example, if the tests are
performed to determine selection and future sporting careers
then this may be deemed to have a ‘high impact’ on the individ-
ual—depending on parental or guardian use of the data—but
this requires further clarification in the light of specific cases.
The American Society for Human Genetics has recently pub-
lished a position statement that recommends that DTC testing
“be discouraged in children until such a time when companies
that provide DTC GT can assure quality, accuracy and validity of
their testing and assure that there is adequate pretesting and
post-testing counselling”.18
Genetic information is potentially sensitive and as such
requires the highest level of security and confidentiality. It is
imperative that any personal data and genetic information that
are linked to an individual should be subject to privacy protection
and security, and cannot be shared without the explicit consent
of the individual, in accordance with current professional guid-
ance and applicable laws on data protection and confidentiality.
It is also important to consider what should occur if a DTC pro-
vider should cease trading or be taken over by a third party.
What are the ethical issues of genetics-based talent
identification programmes?
Genetic information by its very nature means that it is familial.
It reveals facts about persons beyond those who have consented
to tests, whose results may have direct health implications for
other family members. Furthermore the risks of genetic testing
for talent identification may not be immediately obvious
because the risks may be psychological, social and financial. The
psychosocial consequences might include impaired self-esteem,
social stigma and, in terms of sport selection, may include
employment limitation. The testing may also impact on personal
relationships within families or have a life-altering impact on
the behaviour of the individual taking the test.
Consumers of the test (coaches, parents, etc) may secure services
that they falsely believe will steer children as to which sports most
effectively can be pursued according to their genetically derived
data. Such predictions are associated with ethical problems that
vary according to the individual tested. These range from the nar-
rowing of athletic participation opportunities, a heightening of the
dangers of early specialisation, and a failure to engage with what
could be activities that provide a lifetime of satisfaction (in the
absence of athletic success). These might be thought of as infringe-
ments of children’s rights to an open future,19–21 that parents have
a duty to protect. Finally, the use of DTC Genetic Testing is irre-
sponsible when it is provided without genetic counselling.
Notably, the UK Human Genetics Commission and the European
Society of Human Genetics recommend that genetic tests be pro-
vided with appropriate genetic counselling so that test data can be
interpreted in the light of the particular individual, their circum-
stances and the relative predictive power of the test outcomes.
What is the current scientific evidence for genetic testing
for talent identification for sport?
The genetic variants tested most frequently by the companies
providing DTC genetic tests related to sport and exercise in
2015 were those in the ACTN3 and ACE genes, which presum-
ably reflects the fact that more research has been conducted on
those polymorphisms than any others in the context of sport
and exercise. Although the true role of the ACTN3 R577X and
ACE I/D variants in skeletal muscle metabolism and strength
traits remains controversial,22 in meta-analyses the ACE II geno-
type was associated with physical performance (OR=1.23; 95%
CI 1.05 to 1.45), especially endurance performance (OR 1.35;
95% CI 1.17 to 1.55), while ACTN3 RR genotype was asso-
ciated with speed and power performance (OR=1.21; 95% CI
1.03 to 1.42).23 ORs of approximately 1.5 are very small,
however and virtually meaningless for talent identification in
isolation. For example, while an OR of 1.2 for ACTN3 RR
genotype might imply a 20% greater likelihood of being an elite
sprinter than other genotypes, in the UK’s ∼65 million popula-
tion there are an estimated 20 million people of RR genotype—
but only a tiny fraction of those people are elite athletes.
Indeed, the degree of interindividual variability in sprinting per-
formance that can be explained by ACTN3 genotype, for
example, which has been estimated to reach ∼2–3%,24 25 while
based on the broader scientific literature is probably less than
1%. Hence, while there is a little replicated scientific evidence
regarding these ACTN3 and ACE polymorphisms on a commer-
cial basis, and one can understand individuals interested in exer-
cise and sport wishing to learn about their own genetic
composition within these two well-studied genes, the consensus
is that the predictive value of such tests in the context of train-
ing responses or talent identification in sport is virtually zero.26
There is limited information that can be gleaned from dis-
crete, single marker genetic tests at common polymorphisms. It
is totally unwarranted for companies to sell DTC Genetic
Testing based on a single variant as there is absolutely no evi-
dence to claim they provide information on which personal
exercise training or sport decisions can reasonably be made.
Most of the companies identified as offering defined DTC
genetic tests assess a panel of multiple genetic variants (median
6 variants, range 1–27). However, when considering genetic var-
iants beyond those that are reasonably well-studied, the level of
scientific evidence to support the choice of any particular poly-
morphism is extremely weak or non-existent.26–28 While com-
mercial pressures undoubtedly exist, it would be more
responsible to wait for better and stronger scientific evidence
before offering genetic tests commercially. Moreover, counsel-
ling that puts the genetic information—including the limitations
of its usefulness—into proper context is absolutely necessary.
What are the recommendations that can be made from a
scientific perspective on the role of DTC in talent
identification?
Based on the published scientific evidence, the information pro-
vided by DTC is virtually meaningless for prediction and/or
optimisation of sport performance. There is currently no evi-
dence that existing genetic tests provide information that is
useful regarding either predisposition for a particular sport, pre-
diction of the training response likely to occur to a particular
training programme, or predisposition to exercise-related
injury.29 It is unknown at this time whether genetic testing, even
when knowledge and test validity improves dramatically, will
provide information that is not captured within other, trad-
itional non-genetic tests of physiological, anthropometric,
medical and performance characteristics that are already used
routinely in sport and exercise science and medicine. The key
issue is that the question can only be resolved by a comprehen-
sive and highly focused research programme.
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THE CONSENSUS SUMMARY
The science around genetic testing is an emerging field. With
regard to predicting future sporting performance, the scientific
foundation is extremely limited and largely non-existent. There
is concern among the scientific community that the current
level of knowledge is being misrepresented implicitly for com-
mercial purposes. There remains a lack of universally accepted
guidelines and legislation for DTC testing in relation to all
forms of genetic testing and not just for talent identification.
The exercise science and sports medicine community has a
duty of care to provide the most up-to-date advice on issues
relating to health and well-being of athletes. This also relates
to advising sports teams, athletes, parents and children about
the absence of scientific evidence and current limitations of
genetic testing in predicting future sport performance. There is
concern over the lack of clarity of information over which spe-
cific genes or variants are being tested and the almost universal
lack of appropriate genetic counselling for the interpretation of
the genetic data to consumers. Furthermore independent
studies have identified issues relating to quality control by
DTC laboratories with different results being reported from
samples from the same individual. DTC companies must also
better address issues around consent, privacy and ownership of
data if a company should cease trading or be taken over by a
third party.
While further evidence will undoubtedly emerge around the
genetics of sport performance in the future, the data are cur-
rently very limited. The ACTN3 genotype is the most commonly
tested by DTC companies. However, even for this genotype, its
contribution to the degree of inter-individual variability in
sprinting performance is trivial. Consequently, in the current
state of knowledge, no child or young athlete should be
exposed to DTC genetic testing to define or alter training or for
talent identification aimed at selecting gifted children or adoles-
cents. Large scale collaborative projects, such as the Athlome
Project, may help to develop a stronger scientific foundation on
these issues in the future but, currently, there is no place for
DTC testing for predicting sports performance and talent
identification.
An abbreviated consensus statement outlining the key issues
and recommendations are available in online supplementary
appendix A.
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